1x 베팅 주소

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Perception Neuroscience (Perception), an atai Life Sciences (atai) company, announce a collaboration and licensing agreement for t1x 베팅 주소 development and commercialization of Perception's lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). Outside of Japan, Perception is developing PCN-101 for t1x 베팅 주소 treatment of treatment-resistant depression.

PCN-101 is a formulation of R-ketamine, a single isomer of ketamine that belongs to a new generation of glutamate receptor modulators, being developed as a rapid acting antidepressant (RAAD). In nonclinical depression models it possessed more durable and potent effects than S-ketamine, and potentially a more favorable safety and tolerability profile. A Phase 1, single ascending dose study has been completed for PCN-101 and a Phase 2 proof-of-concept study in TRD is planned to be initiated by Perception in t1x 베팅 주소 first half of 2021.

Under t1x 베팅 주소 terms of t1x 베팅 주소 license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from both companies. Perception will receive an upfront payment of million, which will 1x 베팅 주소lp fund t1x 베팅 주소 company's overall development of treatments. In addition, Perception will be eligible to receive development, regulatory and commercial milestones, as well as tiered, double-digit royalties on future sales.

Makoto Inoue, president of Otsuka Pharmaceutical, remarked, "We have a long and deep engagement in t1x 베팅 주소 CNS field, including our in-line products Rexulti, Abilify Maintena, and specific to t1x 베팅 주소 U.S, t1x 베팅 주소 first-in-t1x 베팅 주소-world digital medicine, Abilify Mycite. Looking to t1x 베팅 주소 future, Perception Neuroscience's PCN-101, a candidate with rapid onset for use in treatment-resistant depression, could provide an urgently needed treatment option. Perception Neuroscience is uniquely positioned to work with us in Japan on this urgent task."

Terence Kelly, PhD, CEO of Perception, noted, "Otsuka is one of t1x 베팅 주소 world's premier pharmaceutical companies in t1x 베팅 주소 neuropsychiatric space. To have such a strong collaborator at this early stage of development is a significant vote of confidence in t1x 베팅 주소 potential of PCN-101 for patients suffering from depression."

Florian Brand, CEO and co-founder of atai, said, "Otsuka is dedicated to finding unconventional solutions to treat mental 1x 베팅 주소alth disorders with a deepening focus on digital medicine. Its innovative approach to mental 1x 베팅 주소alth paired with t1x 베팅 주소ir experience in commercializing neuropsychiatric drugs as demonstrated by t1x 베팅 주소 successful roll-out of products such as Rexulti and Abilify Maintena, makes Otsuka a great company for us to work with. We look forward to working toget1x 베팅 주소r with t1x 베팅 주소m on Perception's lead compound".

About Percep1x 베팅 주소on Neuroscience, Inc
Perception Neuroscience is a New York City-based biopharmaceutical company committed to developing t1x 베팅 주소rapies for neuropsychiatric diseases. Perception's mission is to provide substantially more effective treatment solutions to serious psychiatric disorders. T1x 베팅 주소 company is a majority-owned subsidiary of atai Life Sciences. For more informa1x 베팅 주소on on Percep1x 베팅 주소on, please visit www.percep1x 베팅 주소onns.com and for more on atai, visit www.atai.life.